Forge Biologics’ Chief Executive Officer, Timothy J. Miller, Ph.D., will step down following almost five years of leadership at the Company he co-founded in 2020. John Maslowski, Forge’s Chief Commercial Officer, has been appointed as President, CEO, and a member of the Board of Directors, effective October 1, 2024.
 
Over the course of nearly five years, Miller led Forge’s transition from an early-stage venture-backed start-up through late-stage financings, and, most recently, a $620 million acquisition by Ajinomoto Group—a global food and biotechnology company. Under his tenure, Miller successfully grew the company to more than 350 employees, completed the expansion of Forge’s 200,000 square foot manufacturing facility, raised $330 million in funding, and advanced the Company’s lead program for patients with Krabbe disease into clinical trials. 

About John Maslowski

Maslowski is a seasoned biopharmaceuticals leader with over 25 years of industry experience. As the Chief Commercial Officer at Forge since June 2021, he has been directly responsible for building the Company’s commercial strategy and operations, which now supports nearly 50 clients.
 
Maslowski came to Forge after serving as the President and Chief Executive Officer of Castle Creek Biosciences, Inc. He served in the same role at Fibrocell Science, Inc., a NASDAQ listed cell and gene therapy company, from 2016 until it was acquired in 2019. At Fibrocell, he previously served as the Senior Vice President of Scientific Affairs and Vice President of Operations.
 
Maslowski has extensive experience in the field of cell and gene therapy, including advancing D-Fi—a genetically modified autologous fibroblast therapy—to pivotal clinical trials, and LAVIV—a non-modified autologous fibroblast therapy—through U.S. FDA approval and commercialization.
 
“I am honored to lead Forge’s talented team as we continue our important work—enabling access to gene therapies for our clients and the patient communities we serve. It’s an exciting time at Forge. Our team is not only growing, but we’re expanding our technologies and enhancing operational efficiencies to ensure we continue delivering on the remarkable innovations emerging from our industry,” said Maslowski. “I wish Tim all the best in this new chapter of his life. His legacy of innovation and focus on improving patient lives is ingrained in our foundation and will guide us well into the future.”